Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China; Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Eur J Pharm Biopharm. 2019 Sep;142:153-164. doi: 10.1016/j.ejpb.2019.06.005. Epub 2019 Jun 18.
The distribution of nanomedicines inside solid tumors is often restricted to perivascular areas, leaving most distal tumor cells out of reach. This partly explains modest patient benefit of many nanomedicines compared to their free-form counterparts. The objective for this study is to develop a mathematical model to quantitatively analyze this phenomenon and the influencing factors to such perivascular distribution and seek for effective strategies to alleviate this. A spatial tumor distribution model was firstly constructed to mimic the geometrical structure of tumor vessels and the surrounding tumor cells. This tumor model was further integrated with a systemic pharmacokinetics model for nanoparticles. A variety of factors on the tumor spatial distributions of nanomedicines were considered in the model. With the model, we quantified the effect of these influencing factors on tumor delivery efficacy (ID %), the magnitude of heterogeneous distribution (H index), and the effect of enhanced permeability and retention (EPR). In particularly, we compared the spatial distributions of the nanoparticles and the free payloads insides tumors. The model predicted high degrees of distributional heterogeneity for both nanoparticles and free payloads. The degree of heterogeneity and the influencing factors for free payloads were markedly different from those for nanoparticles. We found that nanoparticle diffusion coefficient was the most effective factor in reducing the nanoparticle H index but exerted moderate influence on the free payloads H index. The most effective factor in reducing the H index of free payload was payload diffusion coefficient. The factors that improved free payload distribution were closely associated with higher drug efficacy. In contrast, the factors that improved nanoparticle spatial distributions did not always confer improved anti-tumor efficacy of the delivered drug. These findings highlight the importance of assessing the heterogeneous free payload distribution in tumors for the development of effective nanomedicines.
纳米药物在实体瘤中的分布通常局限于血管周围区域,使大多数远端肿瘤细胞无法到达。这在一定程度上解释了与游离形式相比,许多纳米药物对患者的疗效为何较为有限。本研究的目的是开发一种数学模型,以定量分析这种血管周围分布现象及其影响因素,并寻求缓解这种现象的有效策略。首先构建了一个空间肿瘤分布模型,以模拟肿瘤血管的几何结构和周围的肿瘤细胞。进一步将该肿瘤模型与纳米颗粒的系统药代动力学模型相结合。该模型考虑了纳米药物在肿瘤中的空间分布的各种因素。通过该模型,我们量化了这些影响因素对肿瘤输送效率(ID%)、不均匀分布程度(H 指数)和增强的渗透性和保留效应(EPR)的影响。特别是,我们比较了纳米颗粒和游离药物在肿瘤内部的空间分布。模型预测了纳米颗粒和游离药物在肿瘤内分布具有高度不均匀性。游离药物的不均匀性程度和影响因素与纳米颗粒明显不同。我们发现,纳米颗粒扩散系数是降低纳米颗粒 H 指数的最有效因素,但对游离药物 H 指数的影响适中。降低游离药物 H 指数的最有效因素是药物扩散系数。改善游离药物分布的因素与更高的药物疗效密切相关。相比之下,改善纳米颗粒空间分布的因素并不总是赋予所输送药物更好的抗肿瘤疗效。这些发现强调了评估肿瘤中不均匀的游离药物分布对于开发有效纳米药物的重要性。